PAREXEL OPENS NEW OFFICE IN JAPAN AND FURTHER STRENGTHENS LEADING PRESENCE IN ASIA/PACIFIC REGION
Boston, MA, October 4, 2010 —PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Nagoya, Japan to support a growing demand for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region. This office further expands PAREXEL’s presence in Japan, which includes locations in Tokyo and Kobe. PAREXEL now has 18 offices throughout important biopharmaceutical centers in the Asia/Pacific region, which in addition to Japan also includes a strong presence in Australia, China, India, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand.
“Japan continues to maintain its position as the second largest pharmaceutical market globally, and is among the most mature markets within the Asia/Pacific region. Japan is attractive to our worldwide client base for inclusion in global studies not only for its market potential but also for its high quality data, advanced technologies, and large pool of well-trained professionals. Clients have continued to rely on PAREXEL’s in-depth expertise in Japan as well as our fully-integrated, harmonized global processes and standards to support their programs,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.
“The opening of our office in Nagoya builds on our established presence and long-term, ongoing commitment to Japan. PAREXEL’s expansion in Japan allows us to further assist locally-based clients with regional and global market access opportunities. Our regulatory and clinical experts are supporting what we call ‘Japan plus Asia’ studies since recent regulatory changes allow for inclusion of non-Japanese data for registration purposes. We are also supporting Japan-based biopharmaceutical companies with simultaneous global clinical studies across a broad range of therapeutic areas, and providing eClinical solutions to accelerate the clinical development process,” said Mr. von Rickenbach.
When PAREXEL was founded 28 years ago, the Company began helping clients based in Japan with U.S. regulatory filings. In 1995, PAREXEL opened its first office in Japan in Kobe. Since then, PAREXEL has continued to expand its work with Japanese companies to assist them with the development and commercialization of their products.
The opening of PAREXEL’s latest office in the Asia/Pacific region, where the Company has had a presence for approximately 15 years, reinforces its long-term commitment to providing clients with a high level of service and quality clinical development solutions in this geography. Today, PAREXEL is one of the area’s leading providers of biopharmaceutical services, helping clients design drug development programs and conduct studies regionally and internationally. PAREXEL experts support biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout the Asia/Pacific region.
For information about PAREXEL’s global clinical research services, visit http://www.parexel.com/services-and-capabilities/clinical-research/. For additional information about PAREXEL’s capabilities in Asia and other emerging regions, and to access the white paper entitled “Country-by-country insights into the key challenges and opportunities for development in the Asia/Pacific region” visit http://www.parexel.com/business-challenges/emerging-regions/.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 54 countries around the world, and has approximately 9,720 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2010 as filed with the SEC on August 27, 2010, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.